EP4245366A3 - Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale - Google Patents

Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale Download PDF

Info

Publication number: EP4245366A3
Authority: EP; European Patent Office
Prior art keywords: migalastat; patient; renal impairment; fabry patients; treating fabry
Prior art date: 2017-05-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP23189734.9A

Other languages

German (de)

English (en)

Other versions

EP4245366A9 (fr

EP4245366A2 (fr

Inventor

Jeff Castelli

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Amicus Therapeutics Inc

Original Assignee

Amicus Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-05-30

Filing date

2018-05-30

Publication date

2023-11-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65803261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4245366(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2018-05-30 Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc

2018-05-30 Priority to EP23219949.7A priority Critical patent/EP4324522B1/fr

2018-05-30 Priority to EP24164126.5A priority patent/EP4374918B1/fr

2018-05-30 Priority to EP25176976.6A priority patent/EP4635496A1/fr

2018-05-30 Priority to EP23219933.1A priority patent/EP4327869B1/fr

2018-05-30 Priority to EP23219922.4A priority patent/EP4327868A2/fr

2018-05-30 Priority claimed from PCT/US2018/035032 external-priority patent/WO2018222655A1/fr

2023-09-20 Publication of EP4245366A2 publication Critical patent/EP4245366A2/fr

2023-11-29 Publication of EP4245366A3 publication Critical patent/EP4245366A3/fr

2023-12-06 Publication of EP4245366A9 publication Critical patent/EP4245366A9/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Urology & Nephrology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

EP23189734.9A 2017-05-30 2018-05-30 Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale Withdrawn EP4245366A3 (fr)

Priority Applications (5)

Application Number	Priority Date	Filing Date	Title
EP23219949.7A EP4324522B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP24164126.5A EP4374918B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP25176976.6A EP4635496A1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP23219933.1A EP4327869B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP23219922.4A EP4327868A2 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201762512458P	2017-05-30	2017-05-30
US201862626953P	2018-02-06	2018-02-06
PCT/US2018/035032 WO2018222655A1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP18733415.6A EP3630114B1 (fr)	2017-05-30	2018-05-30	Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale

Related Parent Applications (2)

Application Number	Title	Priority Date	Filing Date
EP18733415.6A Division EP3630114B1 (fr)	2017-05-30	2018-05-30	Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale
EP18733415.6A Division-Into EP3630114B1 (fr)	2017-05-30	2018-05-30	Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale

Related Child Applications (5)

Application Number	Title	Priority Date	Filing Date
EP23219922.4A Division EP4327868A2 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP25176976.6A Division EP4635496A1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP23219949.7A Division EP4324522B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP23219933.1A Division EP4327869B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP24164126.5A Division EP4374918B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale

Publications (3)

Publication Number	Publication Date
EP4245366A2 EP4245366A2 (fr)	2023-09-20
EP4245366A3 true EP4245366A3 (fr)	2023-11-29
EP4245366A9 EP4245366A9 (fr)	2023-12-06

Family

ID=65803261

Family Applications (9)

Application Number	Title	Priority Date	Filing Date
EP24164126.5A Active EP4374918B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP22165669.7A Active EP4062916B1 (fr)	2017-05-30	2018-05-30	Traitement de patients atteints de la maladie de fabry ayant certaines mutations
EP23219949.7A Active EP4324522B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP22165647.3A Withdrawn EP4062915A1 (fr)	2017-05-30	2018-05-30	Migalastat attaché à alpha galactosidase a
EP23219933.1A Active EP4327869B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP18733415.6A Active EP3630114B1 (fr)	2017-05-30	2018-05-30	Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale
EP25176976.6A Pending EP4635496A1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP23219922.4A Withdrawn EP4327868A2 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP23189734.9A Withdrawn EP4245366A3 (fr)	2017-05-30	2018-05-30	Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale

Family Applications Before (8)

Application Number	Title	Priority Date	Filing Date
EP24164126.5A Active EP4374918B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP22165669.7A Active EP4062916B1 (fr)	2017-05-30	2018-05-30	Traitement de patients atteints de la maladie de fabry ayant certaines mutations
EP23219949.7A Active EP4324522B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP22165647.3A Withdrawn EP4062915A1 (fr)	2017-05-30	2018-05-30	Migalastat attaché à alpha galactosidase a
EP23219933.1A Active EP4327869B1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP18733415.6A Active EP3630114B1 (fr)	2017-05-30	2018-05-30	Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale
EP25176976.6A Pending EP4635496A1 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale
EP23219922.4A Withdrawn EP4327868A2 (fr)	2017-05-30	2018-05-30	Méthodes de traitement de patients atteints de la maladie de fabry souffrant d'une insuffisance rénale

Country Status (14)

Country	Link
EP (9)	EP4374918B1 (fr)
CN (4)	CN119587544A (fr)
DK (2)	DK4062916T3 (fr)
ES (2)	ES3002433T3 (fr)
FI (2)	FI4062916T3 (fr)
HR (2)	HRP20240061T1 (fr)
HU (2)	HUE065615T2 (fr)
LT (2)	LT3630114T (fr)
PL (2)	PL4062916T3 (fr)
PT (2)	PT4062916T (fr)
RS (2)	RS65230B1 (fr)
SI (2)	SI3630114T1 (fr)
SM (2)	SMT202500016T1 (fr)
TW (4)	TWI795408B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20220313670A1 (en) *	2019-06-11	2022-10-06	Amicus Therapeutics, Inc.	Methods Of Treating Fabry Disease In Patients Having Renal Impairment
US11833164B2 (en) *	2019-08-07	2023-12-05	Amicus Therapeutics, Inc.	Methods of treating Fabry disease in patients having a mutation in the GLA gene

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012154681A1 (fr) *	2011-05-06	2012-11-15	Amicus Therapeutics	Quantification de gl3 dans l'urine
WO2019017938A1 (fr) *	2017-07-19	2019-01-24	Amicus Therapeutics, Inc.	Traitement de la maladie de fabry chez des patients non soumis à une thérapie enzymatique substitutive (tes) et chez des patients soumis à tes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
WO2007137072A2 (fr) *	2006-05-16	2007-11-29	Amicus Therapeutics, Inc.	Dosages biologiques pour le diagnostic et l'évaluation d'options de traitement de la maladie de fabry
US20100113517A1 (en)	2007-03-30	2010-05-06	Amicus Therapeutics, Inc.	Method for the treatment of fabry disease using pharmacological chaperones
US9999618B2 (en) *	2007-04-26	2018-06-19	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
WO2008134628A2 (fr)	2007-04-26	2008-11-06	Amicus Therapeutics, Inc.	Schémas posologiques pour le traitement de maladies de stockage lysosomal en utilisant des chaperons pharmacologiques
AU2009214648B2 (en) *	2008-02-12	2014-11-13	Amicus Therapeutics, Inc.	Method to predict response to pharmacological chaperone treatment of diseases
CN107088225A (zh) *	2011-03-11	2017-08-25	阿米库斯治疗学公司	治疗法布里病的给药方案
TWI875676B (zh)	2016-07-19	2025-03-11	美商阿米庫斯醫療股份有限公司	治療ert初治的和已經歷ert的患者中之法布瑞氏症

2018
- 2018-05-30 TW TW107118443A patent/TWI795408B/zh active
- 2018-05-30 EP EP24164126.5A patent/EP4374918B1/fr active Active
- 2018-05-30 LT LTEPPCT/US2018/035032T patent/LT3630114T/lt unknown
- 2018-05-30 SI SI201831052T patent/SI3630114T1/sl unknown
- 2018-05-30 HR HRP20240061TT patent/HRP20240061T1/hr unknown
- 2018-05-30 HU HUE18733415A patent/HUE065615T2/hu unknown
- 2018-05-30 EP EP22165669.7A patent/EP4062916B1/fr active Active
- 2018-05-30 RS RS20240113A patent/RS65230B1/sr unknown
- 2018-05-30 CN CN202411682885.8A patent/CN119587544A/zh active Pending
- 2018-05-30 EP EP23219949.7A patent/EP4324522B1/fr active Active
- 2018-05-30 HU HUE22165669A patent/HUE069837T2/hu unknown
- 2018-05-30 CN CN202311285883.0A patent/CN117357524A/zh active Pending
- 2018-05-30 FI FIEP22165669.7T patent/FI4062916T3/fi active
- 2018-05-30 DK DK22165669.7T patent/DK4062916T3/da active
- 2018-05-30 TW TW112150982A patent/TWI894750B/zh active
- 2018-05-30 CN CN202510610323.0A patent/CN120732857A/zh active Pending
- 2018-05-30 PL PL22165669.7T patent/PL4062916T3/pl unknown
- 2018-05-30 SM SM20250016T patent/SMT202500016T1/it unknown
- 2018-05-30 ES ES22165669T patent/ES3002433T3/es active Active
- 2018-05-30 DK DK18733415.6T patent/DK3630114T3/da active
- 2018-05-30 CN CN201880043564.XA patent/CN111278438A/zh active Pending
- 2018-05-30 PL PL18733415.6T patent/PL3630114T3/pl unknown
- 2018-05-30 EP EP22165647.3A patent/EP4062915A1/fr not_active Withdrawn
- 2018-05-30 EP EP23219933.1A patent/EP4327869B1/fr active Active
- 2018-05-30 FI FIEP18733415.6T patent/FI3630114T3/fi active
- 2018-05-30 EP EP18733415.6A patent/EP3630114B1/fr active Active
- 2018-05-30 RS RS20250010A patent/RS66376B1/sr unknown
- 2018-05-30 SM SM20240037T patent/SMT202400037T1/it unknown
- 2018-05-30 EP EP25176976.6A patent/EP4635496A1/fr active Pending
- 2018-05-30 ES ES18733415T patent/ES2970419T3/es active Active
- 2018-05-30 SI SI201831193T patent/SI4062916T1/sl unknown
- 2018-05-30 HR HRP20241738TT patent/HRP20241738T1/hr unknown
- 2018-05-30 EP EP23219922.4A patent/EP4327868A2/fr not_active Withdrawn
- 2018-05-30 LT LTEP22165669.7T patent/LT4062916T/lt unknown
- 2018-05-30 EP EP23189734.9A patent/EP4245366A3/fr not_active Withdrawn
- 2018-05-30 TW TW110119149A patent/TWI775453B/zh active
- 2018-05-30 PT PT221656697T patent/PT4062916T/pt unknown
- 2018-05-30 TW TW112104527A patent/TW202322814A/zh unknown
- 2018-05-30 PT PT187334156T patent/PT3630114T/pt unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2012154681A1 (fr) *	2011-05-06	2012-11-15	Amicus Therapeutics	Quantification de gl3 dans l'urine
WO2019017938A1 (fr) *	2017-07-19	2019-01-24	Amicus Therapeutics, Inc.	Traitement de la maladie de fabry chez des patients non soumis à une thérapie enzymatique substitutive (tes) et chez des patients soumis à tes

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Galafold 123 mg hard capsules ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS", 26 May 2016 (2016-05-26), pages 1 - 50, XP055582182, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/documents/product-information/galafold-epar-product-information_en.pdf> [retrieved on 20190417] *
EMEA: "Galafold", EUROPEAN MEDICINES AGENCY, 1 January 2016 (2016-01-01), XP055861177, Retrieved from the Internet <URL:https://www.ema.europa.eu/en/medicines/human/EPAR/galafold> [retrieved on 20211115] *
EUROPEAN COMMISSION: "granting marketing authorisation under Regulation (EC) No 726/2004 of the European Parliament and of the Council for "Galafold - migalastat", an orphan medicinal productfor human use", EUROPEAN COMMISSION - COMMISSION IMPLEMENTING DECISION, 26 May 2016 (2016-05-26), XP055861180, Retrieved from the Internet <URL:https://www.ema.europa.eu> [retrieved on 20211115] *
JOHNSON FRANKLIN K ET AL: "An open-label study to determine the pharmacokinetics and safety of migalastat HCl in subjects with impaired renal function and healthy subjects with normal renal function", CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT UNITED STATES JUL 2017, CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT UNITED STATES JUL 2017, CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT UNITED STATES JUL 2017, vol. 4, no. 4, 30 June 2015 (2015-06-30), pages 256 - 261, XP009507828, ISSN: 2160-7648, DOI: 10.1002/CPDD.149 *
SKUBAN N BARTH J YU J ET AL: "SP002: Clinical outcomes with migalastat in patients with fabry disease basedondegreeof renalimpairment: Results from phase 3 trials", NEPHROLOGY DIALYSIS TRANSPLANTATION; 55TH ANNUAL CONGRESS OF THE EUROPEAN RENAL ASSOCIATION-EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION, ERA-EDTA 2018, OXFORD UNIVERSITY PRESS, GB; COPENHAGEN, DENMARK, vol. 33, no. Supplement 1, 1 May 2018 (2018-05-01), pages i346, XP009507822, ISSN: 0931-0509, DOI: 10.1093/NDT/GFY104.SP002 *
WILLIAMS H ET AL: "SP004: Effects of long-term migalastat treatment on renal function by baseline proteinuria in patients (PTS) with fabry disease", NEPHROLOGY DIALYSIS TRANSPLANTATION; 55TH ANNUAL CONGRESS OF THE EUROPEAN RENAL ASSOCIATION-EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION, ERA-EDTA 2018, OXFORD UNIVERSITY PRESS, GB; COPENHAGEN, DENMARK, vol. 33, no. Supplement 1, 1 May 2018 (2018-05-01), pages i347 - i348, XP009507821, ISSN: 0931-0509, DOI: 10.1093/NDT/GFY104.SP004 *

Also Published As

Publication number	Publication date
PL3630114T3 (pl)	2024-03-25
CN119587544A (zh)	2025-03-11
FI3630114T3 (fi)	2024-01-30
EP4374918B1 (fr)	2025-07-16
EP3630114A1 (fr)	2020-04-08
EP4062915A1 (fr)	2022-09-28
HUE065615T2 (hu)	2024-06-28
HRP20240061T1 (hr)	2024-03-29
SMT202500016T1 (it)	2025-03-12
SI3630114T1 (sl)	2024-03-29
EP4245366A9 (fr)	2023-12-06
DK4062916T3 (da)	2025-01-13
TW202140000A (zh)	2021-11-01
TW202322814A (zh)	2023-06-16
EP4327869B1 (fr)	2025-12-10
FI4062916T3 (fi)	2025-01-10
TWI795408B (zh)	2023-03-11
EP4635496A1 (fr)	2025-10-22
ES3002433T3 (en)	2025-03-06
CN117357524A (zh)	2024-01-09
EP3630114B1 (fr)	2023-11-01
EP4324522A2 (fr)	2024-02-21
EP4327868A2 (fr)	2024-02-28
EP4374918A3 (fr)	2024-08-14
SMT202400037T1 (it)	2024-03-13
EP4324522A3 (fr)	2024-05-22
SI4062916T1 (sl)	2025-04-30
TWI894750B (zh)	2025-08-21
PT3630114T (pt)	2024-02-01
EP4062916B1 (fr)	2024-10-09
TW202440104A (zh)	2024-10-16
HRP20241738T1 (hr)	2025-02-28
TWI775453B (zh)	2022-08-21
PT4062916T (pt)	2025-01-13
EP4245366A2 (fr)	2023-09-20
EP4327869A2 (fr)	2024-02-28
EP4324522B1 (fr)	2025-12-10
EP4374918A2 (fr)	2024-05-29
RS65230B1 (sr)	2024-03-29
CN111278438A (zh)	2020-06-12
EP4062916A1 (fr)	2022-09-28
RS66376B1 (sr)	2025-02-28
TW201900165A (zh)	2019-01-01
EP4327869A3 (fr)	2024-05-22
LT3630114T (lt)	2024-02-12
HUE069837T2 (hu)	2025-04-28
DK3630114T3 (da)	2024-01-29
PL4062916T3 (pl)	2025-03-17
ES2970419T3 (es)	2024-05-28
CN120732857A (zh)	2025-10-03
LT4062916T (lt)	2025-01-10

Publication	Publication Date	Title
MX391565B (es)	2025-03-21	Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
NZ790449A (en)	2025-08-29	Treatment of fabry disease in ert-naïve and ert-experienced patients
MX2023005455A (es)	2023-07-27	Metodos de tratamiento de la insuficiencia cardiaca mediante la administracion de omecamtiv mecarbil.
MY199967A (en)	2023-11-30	Combinations of lsd1 inhibitors for use in the treatment of solid tumors
EP4424328A3 (fr)	2024-12-04	Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
WO2011014255A8 (fr)	2012-03-15	Traitement de la maladie de crohn au moyen de laquinimod
PH12021553102A1 (en)	2023-10-09	Methods of treating fabry disease in patients having renal impairment
HK1202776A1 (en)	2015-10-09	Use of laquinimod for treating crohn's disease patients who failed first-line anti-tnf therapy
AU2018326364A1 (en)	2020-04-09	Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease
EP4316589A3 (fr)	2024-04-24	Traitement de patients atteints de la maladie de fabry classique
EP3590338A3 (fr)	2020-03-18	Traitements médicaux à base d'anamoréline
CL2023000296A1 (es)	2023-08-25	Uso de dexpramipexol para el tratamiento del asma moderado a grave
PH12015502465A1 (en)	2016-02-22	Use of landiolol hydrochloride in the long-term treatment of tachyarrhythmias
WO2019010301A8 (fr)	2020-05-22	Traitement de cardiopathies par inhibition de l'action des protéines d'ancrage aux protéines kinases a (makap) du muscle
MX2021003606A (es)	2021-08-16	Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv.
EP4245366A3 (fr)	2023-11-29	Migalastat pour le traitement de patients atteints de la maladie de fabry souffrants d'une insuffisance rénale
MX2019008076A (es)	2019-08-29	Regimen terapeutico para el tratamiento de fabry usando alfa-galactosidasa estabilizada.
MX2021011289A (es)	2021-11-03	Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas.
AR111971A1 (es)	2019-09-04	Métodos para tratar pacientes con enfermedad de fabry que tienen insuficiencia renal
ATE502637T1 (de)	2011-04-15	Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum
EA201992869A1 (ru)	2020-03-27	Способы лечения пациентов с болезнью фабри, у которых имеется почечная недостаточность
CA3069989C (fr)	2025-05-06	Méthodes de traitement de symptômes de gastroparésie au moyen de velusetrag
UA92908C2 (ru)	2010-12-27	Соединения, производные от 5-тиоксилозы, и их терапевтическое применение
AR109102A1 (es)	2018-10-31	Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
RU2009124997A (ru)	2011-01-10	Способ лечения туберкулезного хориоретинита

Legal Events

Date	Code	Title	Description
2023-08-18	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2023-08-18	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED
2023-09-20	AC	Divisional application: reference to earlier application	Ref document number: 3630114 Country of ref document: EP Kind code of ref document: P
2023-09-20	AK	Designated contracting states	Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-10-25	REG	Reference to a national code	Ref country code: DE Ref legal event code: R079 Free format text: PREVIOUS MAIN CLASS: A61P0013120000 Ipc: A61K0031445000
2023-10-27	PUAL	Search report despatched	Free format text: ORIGINAL CODE: 0009013
2023-11-29	AK	Designated contracting states	Kind code of ref document: A3 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2023-11-29	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 13/12 20060101ALI20231025BHEP Ipc: A61K 31/445 20060101AFI20231025BHEP
2024-05-24	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40101630 Country of ref document: HK
2024-09-20	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2024-10-23	18D	Application deemed to be withdrawn	Effective date: 20240530